Tag: enrollment

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- The Kevin Kuykendall Grant for Student Athletes officially opens its application cycle, offering a dedicated financial award to undergraduate students nationwide who balance academic pursuits with athletic ambitions. Founded by seasoned entrepreneur and former professional baseball player Kevin D. Kuykendall, this initiative supports the next generation of sports industry leaders, including competitive athletes, future coaches, and aspiring sports management professionals.

"Mastery & Wellness: How to Thrive as a Physician" Offers 12 Physician CME Credits

Closed transaction provided $15 million in New Markets Tax Credit financing for the construction of a new K-12 public charter school in the Bronx.

New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx, a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing membership costs, insurance-supported GLP-1 treatment options, compounded medication pricing, bundled care plans, and subscription terms. The pricing overview is intended to provide prospective patients with greater transparency regarding the potential costs associated with RoenRx's weight-management services and available treatment pathways.

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the “Class Period”), of the important August 7, 2026 lead plaintiff deadline.

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.